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Abstract
Objective—Individuals with elevated prothrombin, including those with the prothrombin
G20210A mutation, have increased risk of venous thrombosis. Although these individuals do not
have increased circulating prothrombotic biomarkers, their plasma demonstrates increased tissue
factor-dependent thrombin generation in vitro. The objectives of this study were to determine the
pathologic role of elevated prothrombin in venous and arterial thrombosis in vivo, and distinguish
thrombogenic mechanisms in these vessels.
Approach and results—Prothrombin was infused into mice to raise circulating levels. Venous
thrombosis was induced by electrolytic stimulus to the femoral vein or inferior vena cava ligation.
Arterial thrombosis was induced by electrolytic stimulus or ferric chloride application to the
carotid artery. Mice infused with prothrombin demonstrated increased tissue factor-triggered
thrombin generation measured ex vivo, but did not have increased circulating prothrombotic
biomarkers in the absence of vessel injury. Following venous injury, elevated prothrombin
increased thrombin generation and the fibrin accumulation rate and total amount of fibrin ~3-fold,
producing extended thrombi with increased mass. However, elevated prothrombin did not
accelerate platelet accumulation, increase the fibrin accumulation rate, or shorten the vessel
occlusion time following arterial injury.
Conclusions—These findings reconcile previously discordant findings regarding thrombin
generation in hyperprothrombinemic individuals measured ex vivo and in vitro, and show elevated
prothrombin promotes venous, but not arterial, thrombosis in vivo.
INTRODUCTION
Arterial thrombosis and venous thrombosis/thromboembolism are traditionally regarded as
distinct diseases with respect to their epidemiology and treatment strategies (reviewed in1,2).
The presence of certain non-overlapping risk factors suggests that distinct features in the
arterial and venous environments confer differential pathophysiology. Venous thrombosis is
often associated with acquired or inherited plasma hypercoagulability and is thought to be
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triggered by expression of cell adhesion molecules and procoagulant activity on intact
endothelium in low shear. In contrast, arterial thrombosis is typically associated with
atherosclerotic plaque rupture and exposure of subendothelial cells and highly procoagulant
material (tissue factor [TF] and collagen) to blood in high shear. Consequently, venous
thrombi are high in erythrocyte and fibrin content; whereas, arterial thrombi are platelet-
rich. Treatment strategies to minimize venous thrombosis/thromboembolism and arterial
thrombosis (anticoagulants and platelet antagonists, respectively) have reduced efficacy vice
versa1–3, supporting the premise that unique pathophysiological mechanisms promote
thrombosis in veins and arteries.
Individuals with elevated prothrombin (hyperprothrombinemia), including those with the
G20210A mutation in the prothrombin 3′-untranslated region4,5, have ~3-fold increased risk
for venous thrombosis. In particular, the G20210A mutation is associated with ~115–170%
of normal prothrombin activity levels.4–6 This mutation is present in 1–4% of the general
European population7, making it the 2nd most common genetic risk factor for venous
thrombosis in Caucasians. In contrast, association of either elevated prothrombin or the
G20210A mutation with arterial thrombosis is unclear.8,9 Although the G20210A mutation
has been weakly-associated with arterial disease10 including coronary heart disease11,
ischemic stroke12, and risk of myocardial infarction in young women13 and men14, other
investigations have failed to support these findings in patients with cerebral ischemia15,16,
myocardial infarction17, or general arterial events18. Patient heterogeneity may reconcile
differences between these studies since arterial risk is increased in patients with additional
risk factors (e.g., smoking, hypertension, diabetes and/or obesity)13,14; however, the
independent association between elevated prothrombin and arterial thrombosis is difficult to
discern in a human cohort and remains unresolved.
The operant pathological mechanisms of hyperprothrombinemia in either venous or arterial
vascular beds are also unknown. Individuals with elevated prothrombin do not have
increased circulating prothrombin fragment 1.2 levels6, suggesting thrombosis does not
result from constitutive activation of coagulation. However, in vitro studies show that
following coagulation activation, high prothrombin levels increase thrombin
generation19–22, induce activated protein C resistance23, and promote formation of abnormal
fibrin networks19 in clots that resist fibrinolysis23,24. These findings suggest elevated
prothrombin levels promote thrombosis; however, this effect has never been directly
demonstrated in vivo.
The objectives of the present study were to define the prothrombotic role(s) of elevated
prothrombin in vivo and distinguish pathologic mechanisms differentiating these effects in
venous and arterial thrombosis. We found that elevated prothrombin increased plasma
thrombin generation ex vivo following TF-dependent initiation of coagulation, but did not
activate coagulation or increase baseline thrombin generation in vivo in the absence of overt
vascular injury. Following vascular injury, elevated prothrombin increased in vivo thrombin
generation, but did not increase the rate of platelet accumulation in either arterial or venous
thrombi. Elevated prothrombin increased the rate of fibrin deposition and produced larger
thrombi in models of venous thrombosis. In contrast, elevated prothrombin did not increase
the rate of fibrin deposition or shorten the time to occlusion (TTO) in models of arterial
thrombosis. These data are the first to show that elevated prothrombin levels directly
promote venous thrombosis in vivo, and show elevated prothrombin has little to no
independent contribution to arterial thrombosis in the absence of additional risk factors.
MATERIALS AND METHODS
Materials and methods are available in the Supplemental Materials.
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Human prothrombin is active in murine plasma
The in vivo hyperprothrombinemia model was developed by infusing mice with human
prothrombin. Human prothrombin and the thrombin B chain have 81.4% and 88.8% amino
acid identity with murine prothrombin and thrombin, respectively, and highly-conserved
substitutions in non-identical residues.25 Human and mouse thrombin bind and cleave
human and mouse fibrinogen26, activate platelets to form aggregates with pseudopodia27,
bind murine thrombomodulin, and support activated protein C generation28,29. To assess the
ability of human (pro)thrombin to support thrombin generation in murine plasma, murine
plasma was spiked with vehicle or murine or human prothrombin to 200% (final,
endogenous plus spiked human prothrombin) and thrombin generation was measured by
calibrated automated thrombography in the absence and presence of 200 nM murine
thrombomodulin. Thrombin generation peaks were 49.4±7.2, 82.4±13.8 and 90.4±5.2 nM
(mean±SD, n=2–3) for plasma plus vehicle, plasma plus murine prothrombin, or plasma
plus human prothrombin, respectively, and addition of murine thrombomodulin reduced the
thrombin peaks by 73, 74, and 64%, respectively (Supplemental Figure I). These data
demonstrate that human (pro)thrombin is compatible with the murine procoagulant and
anticoagulant systems.
In the absence of vessel injury, elevated prothrombin does not activate coagulation
Platelet-poor plasma (PPP) from patients with elevated prothrombin demonstrates increased
thrombin generation ex vivo6,22; however, these patients do not have higher circulating
prothrombin fragment 1.2 compared to age-matched controls.6 We hypothesized that
elevated prothrombin does not independently cause thrombin generation in the absence of
vascular injury, but increases thrombin generation following TF exposure. To test this
hypothesis, we infused prothrombin (to 300% of normal levels; total prothrombin equals
endogenous murine prothrombin plus infused human prothrombin) or vehicle (20 mM
HEPES (pH 7.4)/150 mM NaCl (HBS), Control) into uninjured mice and measured
prothrombin antigen by western blotting, thrombin generation ex vivo by calibrated
automated thrombography, and thrombin-antithrombin complex (TAT) levels by ELISA 12
hours after infusion. Human prothrombin still circulated in mice 12 hours post-infusion and
was strongly detected by the rabbit anti-human prothrombin antibody (Supplemental Figure
II). Consistent with humans, thrombin generation was significantly elevated in PPP from
prothrombin-infused mice compared to controls (49.5±2.1 versus 39.3±2.5 peak thrombin,
respectively, mean±SEM, P<0.04) (Figure 1A) following initiation of coagulation ex vivo.
However, also consistent with that seen in humans, circulating TAT levels in mice with
elevated prothrombin, even at this high level, were not elevated compared to controls
(2.4±1.4 versus 3.8±4.0 ng/mL, respectively, mean±SEM, P=0.26) (Figure 1B). These data
reconcile outwardly discordant findings regarding thrombin generation in
hyperprothrombinemic individuals measured ex vivo and in vitro by showing that elevated
prothrombin does not increase baseline hemostatic “idling” in the absence of vascular injury,
but augments thrombin generation following a procoagulant trigger.
Elevated prothrombin accelerates fibrin deposition and produces larger thrombi in venous
thrombosis models
To characterize the effect of elevated prothrombin on venous thrombosis in vivo, we first
triggered thrombosis in the murine femoral vein via electrolytic injury and used intravital
fluorescence detection to characterize the temporal and spatial contributions of elevated
prothrombin to thrombus formation. The electrolytic injury model induces mural thrombus
formation via iron-mediated injury that causes early platelet accumulation followed by fibrin
accumulation30 (Figure 2A, Supplemental Videos I, II). Thrombus formation in this model
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is reduced by heparin, consistent with the sensitivity of venous thrombosis to thrombin
generation.31 We tested 2 levels of prothrombin: 130% and 200% (final); these levels were
chosen to approximate the mean and upper end of the pathophysiologic range. Neither
prothrombin concentration significantly increased the rate or total amount of platelet
accumulation in femoral vein thrombi (Figures 2B, 2D). However, the plasma prothrombin
level showed a dose-dependent effect on fibrin accumulation in the vein. At 60 minutes,
fibrin accumulation in mice infused to 130% and 200% prothrombin was 1.7- (p<0.06) and
3.5- (p<0.002) fold higher, respectively, than control mice (Figure 2C), and mice infused
with 200% prothrombin exhibited a significantly (2.3-fold, p=0.006) increased fibrin
accumulation rate than control mice (Figure 2D). Furthermore, in contrast to control thrombi
that remained relatively localized to the thrombus induction site, thrombi in prothrombin-
infused mice showed considerable downstream elongation of a mass containing both fibrin
and platelets (Supplemental Videos I, II).
We also characterized the effect of elevated prothrombin on venous thrombosis in an
inferior vena cava (IVC) ligation (stasis) model that triggers venous thrombosis via vessel
distention, blood stasis, and dysfunction (exposure of vessel wall TF) of intact
endothelium.32 For both control and prothrombin-infused mice, circulating TATs were
significantly higher in mice that underwent IVC ligation than in mice that did not (Figure
3A), demonstrating activation of coagulation following vessel ligation. Circulating
prothrombin was spiked to 300% so that levels remained elevated for the duration of
thrombus formation (12 hours). Following IVC ligation, TATs were more than 2-fold higher
in prothrombin-infused mice compared to control mice (47.9±6.5 versus 21.2±4.5 ng/mL,
respectively, mean±SEM, p<0.009, Figure 3A), suggesting elevated prothrombin augmented
thrombin generation during venous thrombogenesis. Following IVC ligation, all
prothrombin-infused and control mice developed thrombi within 12 hours. Similar to that
seen in the electrolytic injury model, thrombi in prothrombin-infused mice were
significantly larger than thrombi in control mice (27.6 (26.1–43.6) versus 22.6 (9.5–27.7)
mg, respectively, median (range), p=0.01, Figure 3B), and in some mice extended into the
iliac branches. Together, these data show that elevated prothrombin augments venous
thrombus formation in vivo by increasing thrombin generation and intravascular fibrin
deposition.
Elevated prothrombin has little to no effect on the TTO or rate of platelet accumulation in
arterial thrombosis models
We then used the electrolytic injury and real-time fluorescence detection method to measure
the kinetics of platelet and fibrin accumulation in control and prothrombin-infused mice
during arterial thrombosis (Figures 4A–4D, Supplemental Videos III, IV). Platelet
accumulation in the artery was 3.2-fold faster (p<0.003) than that in the vein (Figure 4B, 4D
vs 2B, 2D) and was complete within 10 minutes, consistent with the strongly platelet-
dependent mechanism associated with arterial thrombosis. At 60 minutes, arterial thrombi
also had 50% less fibrin deposition than venous thrombi (Figure 4C vs 2C), further
illustrating mechanistic differences in thrombus formation in these two vessels. Arterial
clots exhibited some embolization, indicated by the loss of mean fluorescence. As in the
venous model, prothrombin levels were raised to 130 and 200% of normal (final). Neither
prothrombin concentration significantly increased either the rate or total amount of platelet
accumulation, or the rate of fibrin accumulation in carotid artery thrombi (Figures 4B–4D).
Elevated prothrombin increased fibrin deposition at 60 minutes (~2-fold, Figure 4C), but
this difference did not reach statistical significance (P<0.085).
We then tested the effect of elevated prothrombin in a second model of arterial thrombosis.
The FeCl3 application/carotid artery model triggers arterial thrombosis via generation of
reactive oxygen species and exposure of collagen, resulting in a platelet-rich thrombus.33–35
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Since neither prothrombin concentration significantly altered arterial thrombus formation in
the electrolytic model, we only tested the higher concentration of prothrombin (infusing to
200%, final) in the FeCl3/carotid artery model. Prothrombin infusion transiently elevated
TAT levels (12.6±3.2 ng/mL), likely reflecting mild activation of coagulation from the
venous infusion or trace (<0.004%) thrombin contamination in the prothrombin concentrate
that was immediately inhibited by endogenous antithrombin (present in 1000-fold excess).
This low thrombin level does not have any physiologic effects.36,37 For both control and
prothrombin-infused mice, circulating TATs were significantly higher in mice that
underwent FeCl3 injury than in mice that did not (Figure 4E), demonstrating activation of
coagulation following FeCl3 injury. Following FeCl3 injury, TATs levels were significantly
different between control and prothrombin-infused mice (13.9±1.7 versus 23.5±2.6, for
control and prothrombin-infused mice, respectively, P<0.007, Figure 4E). However, the
absolute increase in TAT levels over baseline was similar in both control and prothrombin-
infused mice, suggesting arterial injury activated coagulation to a similar degree in both
groups. Consistent with this observation, both control and prothrombin-infused mice
developed stable, occlusive thrombi, and the time to vessel occlusion in prothrombin-infused
mice was not different from controls (9.5 [4.3–40.0] versus 6.4 [4.5–8.5] minutes),
respectively, median [range], Figure 4F). Thus, elevated prothrombin did not significantly
increase platelet or fibrin accumulation during arterial thrombus formation or shorten the
time to artery occlusion. Together, these data show that although elevated prothrombin
promotes venous thrombus formation, it does not significantly augment arterial (platelet-
dependent) thrombosis.
DISCUSSION
Elevated prothrombin is a well-established risk factor for venous thrombosis, but its
relationship to arterial thrombosis is unclear. Using state-of-the-art in vivo models of venous
thrombosis and arterial thrombosis, we show that elevated prothrombin did not increase
baseline prothrombotic markers in unchallenged mice, but did increase thrombin generation
following venous injury. The presence of elevated prothrombin did not accelerate
intravascular platelet accumulation following either venous or arterial injury. In venous
thrombosis models, mice with elevated prothrombin exhibited an increased rate and amount
of fibrin accumulation, thrombus extension and formation of thrombi with increased mass.
However, in arterial thrombosis models, elevated prothrombin slightly (non-significantly)
increased the total amount of fibrin deposited, but did not increase the rate of fibrin
accumulation or shorten the TTO. These findings suggest elevated prothrombin has little to
no independent contribution to arterial thrombosis, and are the first to show that elevated
prothrombin levels directly promote venous thrombosis in vivo.
The choice of murine thrombosis model for investigating human thrombosis has been the
subject of considerable debate because many models fail to recapitulate key aspects of the
arterial and venous thrombogenic processes.38 An important strength of our study was the
use of complementary arterial and venous models to delineate both kinetic processes and
their consequences for thrombus composition. Complementary, integrated information from
the two arterial models and two venous models reveals both common and vascular bed-
specific processes operant in these vessels that are consistent with the histological
appearance of arterial and venous thrombi isolated from humans. Arterial injury produced
rapid platelet accumulation; whereas, venous injury resulted in slower thrombus formation
with fibrin accumulation. We used models that produced both occlusive (FeCl3/carotid and
IVC) and non-occlusive (electrolytic injury) thrombi. Findings were consistent within
vessels, but differed between arteries and veins, suggesting these models are sensitive to the
unique physical and biochemical environments within the different vessels.
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We detected both common and vascular bed-specific effects of elevated prothrombin on
arterial and venous thrombosis. Elevated prothrombin significantly augmented endogenous
thrombin generation in the venous model, but only slightly (non-significantly) in the arterial
model (Figures 3A, 4E). Consistent with our findings, a recent study showed that ApoE-/-
mice expressing half of the prothrombin level of wild type mice (FII-/+) are not protected
from arterial thrombosis, supporting the conclusion that variation in the prothrombin level
does not mediate arterial occlusion times.39 Notably, although thrombin is a potent agonist
for platelet activation, elevated prothrombin did not accelerate the rate of platelet
accumulation in either arteries or veins (Figures 2D, 4D). These findings are consistent with
our prior observation that 5% prothrombin is both necessary and sufficient to maximize
platelet activation.19 Consequently, elevated prothrombin did not accelerate arterial
occlusion, a platelet-dominated process. In contrast, the increased thrombin generation
significantly increased fibrin deposition and therefore, venous thrombosis, a fibrin-
dominated process. We previously showed that elevated prothrombin also promotes the
thrombin concentration-dependent formation of plasma clots with an abnormally dense
fibrin network.19 Although fibrin network structure is difficult to assess in thrombi in the
presence of cells, combined, these results suggest that in veins, elevated prothrombin
promotes thrombi with fibrin networks that have both increased mass and increased network
density. Both properties are associated with increased clot stability in vitro and in vivo, and
have been correlated with increased thrombosis risk.40
It is interesting that while elevated prothrombin did not accelerate arterial occlusion after
FeCl3 injury, elevated plasma factor VIII does41–43. Both elevated prothrombin and elevated
factor VIII increase thrombin generation in vitro19–21,43,44 and in vivo (Figure 3A and 41).
However, elevated factor VIII significantly shortens the lag time to platelet aggregation in
vitro41 and trends towards increased platelet accumulation in vivo43; whereas, elevated
prothrombin did not significantly change the rate of platelet aggregation in vitro19 or in vivo
(Figures 2D, 4D). These data suggest elevated factor VIII modulates an early (amplification)
phase of coagulation when thrombin levels are relatively low and platelet activation is taking
place. Consequently, platelet-dependent arterial thrombosis models are sensitive to the
effects of elevated factor VIII, but not to elevated prothrombin. This observation is
consistent with the premise that procoagulant factors have complementary, but distinct, roles
in different phases of coagulation.45
Previous studies on the association between elevated prothrombin and arterial thrombosis
(myocardial infarction or ischemic stroke) have been inconsistent, showing either no or a
modest relationship.8–18 One explanation for these differences is that risk is present only in
specific groups. Of interest are observations that relative risk increases when another
identifiable cardiovascular risk factor is also present and appears higher than from either risk
factor alone, suggesting an additive or synergistic interaction.13,14 A strength of our murine
model in which prothrombin levels were acutely elevated in healthy wild type mice is the
clear absence of other risk factors. Nonetheless, the co-existence of additional known or
unidentified risk factors may augment the positive associations detected in prior studies with
human cohorts. For example, on an atherosclerosis-prone background (ApoE-/-), chronic
plasma hypercoagulability (TMPro/Pro) increases atherogenesis and plaque formation, both
of which are associated with atherothrombosis, and reduced prothrombin levels attenuate
atherosclerotic lesion formation.39
This study has potential limitations. First, we used human prothrombin to increase
circulating levels in the mouse. However, published studies25–29 as well as our data show
human prothrombin is stable in murine circulation and participates in murine pro- and
anticoagulant pathways. Moreover, the infusion strategy enabled us to precisely control the
level of circulating prothrombin. Second, the infusion model used in these experiments does
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not reflect pathologic effects that chronic exposure to elevated prothrombin could have on
the vasculature. Atherosclerotic disease reflects chronic vascular injury with occurrences of
acute injury (plaque disruption and TF exposure). However, a major strength of the infusion
model is that it enabled us to isolate and investigate the immediate, direct effects of elevated
prothrombin on thrombus formation. These data on acute effects will be critical for
interpreting findings from mice with genetically-induced chronic plasma hypercoagulability
(e.g., factor V Leiden mice); comparison of short-term and long-term exposure to
hypercoagulability is likely to reveal interesting mechanisms that predispose these
individuals to thrombosis. Third, the thrombosis models we used differed in methodologic
aspects, including anesthesia and analgesia protocols. However, the observation that
elevated prothrombin exhibited consistent effects in each of the venous and each of the
arterial models suggests the observed effects were not due to the methodologies, but to the
prothrombin level, itself. Finally, the arterial and venous models used in this study were
sensitive to thrombus formation, but did not reflect additional effects elevated prothrombin
may have on thrombus stability. For example, although groups have demonstrated increased
activation of the thrombin activatable fibrinolysis inhibitor in plasma with increased
prothrombin, we did not evaluate the long-term resistance of thrombi to fibrinolysis.
In summary, our findings demonstrate that elevated prothrombin does not trigger
endogenous thrombin generation in the absence of vascular injury, suggesting that in lieu of
a signal that initiates coagulation, plasma hypercoagulability is not independently
prothrombotic. These data suggest that increased coagulation biomarkers (e.g., fragment 1.2
or TATs) indicate vascular dysfunction that, when coupled to additional plasma
prothrombotic potential, promote thrombosis. Our findings further show that elevated
prothrombin increases thrombin generation following vascular injury. Elevated prothrombin
does not accelerate platelet activation in either the artery or the vein, but significantly
increases the rate and amount of fibrin deposition following venous injury. These findings
are consistent with findings that elevated prothrombin is associated with venous thrombosis
in humans4–6,46, but is only weakly associated with arterial thrombosis in the absence of
other risk factors.13–18,46 These results support the relevance of murine thrombosis models
to studies of hypercoagulability-related thrombosis in humans. Integrating complementary in
vivo models is a powerful approach to investigate the underlying mechanisms of hemostatic
and thrombotic processes.
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Elevated plasma prothrombin, including that associated with the common G20210A
prothrombin mutation, is associated with significantly increased thrombosis risk. Our
findings demonstrate that elevated prothrombin does not trigger thrombin generation in
the absence of vascular injury, suggesting that in lieu of a signal that initiates
coagulation, plasma hypercoagulability does not independently causes thrombosis.
However, following venous, but not arterial injury, elevated prothrombin accelerates
fibrin accumulation and increases thrombus growth. These findings are the first to
identify a causative mechanism by which elevated prothrombin promotes thrombosis in
vivo. This study shows the importance of using integrated, complementary murine
thrombosis models to understand hypercoagulability-related thrombosis in humans.
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Figure 1. In the absence of vessel injury, elevated prothrombin does not activate coagulation
HBS (Control) or human prothrombin was infused into mice via tail vein injection to 300%,
final (mouse plus human). Twelve hours after infusion, blood was drawn from the IVC into
3.2% sodium citrate and processed to PPP. A) PPP from mice infused with prothrombin (to
300%) or HBS (Control) was diluted 1:3 and coagulation was triggered by addition of TF/
lipid. Thrombin generation was measured by calibrated automated thrombography (n=3/
group). B) TAT levels were measured by ELISA (n=5/group). Bars show mean±SEM.
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Figure 2. Elevated prothrombin increases the rate and extent of fibrin deposition following
electrolytic injury to the femoral vein
Mice were infused with vehicle (control) or prothrombin to 200% of normal. Thrombosis
was induced by electrolytic injury as described in Methods. A) Representative images of
platelet and fibrin accumulation 60 minutes after induction of femoral vein thrombosis via
application of electric current are shown. Flow is from left to right; field dimensions are 3.20
x 0.85 mm (width x height). B–C) Relative fluorescence intensity of platelet (B) and fibrin
(C) accumulation following electrolytic injury to the femoral vein (mean±SEM, n=8/group,
*P<0.002). Symbols are: control (open circles) and prothrombin-infused (closed triangles,
130%; closed circles, 200%). D) Maximum rate of platelet and fibrin accumulation during
femoral vein thrombus formation following electrolytic injury (mean±SEM, n=8/group).
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Figure 3. Elevated prothrombin produces larger venous thrombi by increasing thrombin
generation following IVC ligation
A) IVC stasis was induced in mice infused with prothrombin (to 300%) or vehicle control.
Twelve hours after ligation, blood was collected into citrate from just above the ligation site.
TAT levels were measured from ligated (n=6–8/group) and uninjured mice (n=5/group) in
parallel. Bars show mean±SEM. B) Twelve hours after ligation, the IVCs plus thrombi were
excised and weighed. The box plot indicates medians and upper and lower quartiles (n=6–8/
group).
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Figure 4. Elevated prothrombin does not increase thrombin generation or the rate of platelet or
fibrin accumulation, and does not shorten the TTO in arterial injury models
A) Mice were infused with vehicle (Control) or prothrombin to 130 or 200% of normal.
Thrombosis was induced by electrolytic injury as described in Methods. Representative
images of platelet and fibrin accumulation 60 minutes after induction of carotid artery
thrombosis via electrolytic injury are shown. Flow is from left to right; field dimensions are
3.20 x 0.85 mm (width x height). B–D) Relative fluorescence intensity of platelet (B) and
fibrin (C) accumulation following electrolytic injury to the carotid artery (mean±SEM, n=7–
8/group). Symbols are: control (open circles) and prothrombin-infused (closed triangles,
130%; closed circles, 200%). D) Maximum rate of platelet and fibrin accumulation during
carotid artery thrombosis following electrolytic injury (mean±SEM, n=7–8/group). E) Mice
were infused with vehicle (Control) or prothrombin to 200% of normal. Thrombosis was
induced by 7.5% FeCl3 application to the carotid artery for 2 minutes. Following thrombus
formation, blood was collected from the IVC into citrate and processed to PPP. TAT levels
were measured in FeCl3-treated (n=7–10/group) and uninjured mice (n=4/group) in parallel.
Bars show mean±SEM. F) Following FeCl3 injury, the TTO was determined by flow probe.
The box plot indicates medians and upper and lower quartiles (n=10/group); the open circle
indicates one mouse that did not occlude.
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